stockrow
Saturday 7 November 2026
Export QNTM’s income statement to Excel — free account
Quantum Biopharma Ltd.
QNTM Healthcare Biotechnology
- EPS
- +85.5%
- Free cash flow
- +5.88%
Quarter to June 2026, against a year earlier
2.11
0.00
0.00%
Follow QNTM
Alert me
Target Price Range
Analyst price targets
Free accountTen years at a glance Fiscal years to December
| Ten-year view | Analyst estimates Powerpack | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM Jun ’26 | Trend | 10 yrs | 2026e | 2027e | 2028e | Next 3/yr |
| Income, $m | ||||||||||||||||||
| Income, $m | Revenue | — | — | 0 | — | — | — | — | — | — | — | 0 | — | — | — | — | — | |
| Gross margin, % | — | — | 100.00 | (1,331.03) | 0.00 | 0.00 | 0.00 | — | — | — | 0.00 | (100.0) pt | ||||||
| EBT | 0 | (4) | (18) | (34) | (28) | (34) | (27) | (18) | (15) | (27) | (25) | +74.8% | ||||||
| EBT margin, % | 0.00 | 0.00 | (25,578.54) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.0 pt | ||||||
| Net income | 0 | 0 | (18) | (34) | (28) | (34) | (27) | (18) | (15) | (27) | (25) | +74.8% | ||||||
| Per share, $ | ||||||||||||||||||
| Per share, $ | Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | n/m | |||||
| Earnings | (0.03) | (0.66) | (0.96) | (360.39) | (171.43) | (65.58) | (39.61) | (29.87) | (13.12) | (8.20) | (5.49) | +86.5% | ||||||
| Cash flow | (0.01) | (0.03) | (0.78) | (126.15) | (103.13) | (38.55) | (47.50) | (17.78) | (6.05) | (2.51) | (0.82) | +78.0% | ||||||
| Capex | 0.00 | 0.00 | (0.17) | (6.40) | 0.00 | (0.93) | (0.61) | 0.00 | (0.88) | (0.95) | (0.52) | n/m | ||||||
| Free cash flow | (0.01) | (0.03) | (0.95) | (132.55) | (103.13) | (39.48) | (48.11) | (17.78) | (6.93) | (3.46) | (1.34) | +84.5% | ||||||
| Book value | 0.08 | 2.32 | 2.15 | 333.74 | 195.73 | 100.58 | 51.20 | 21.20 | 9.18 | 1.55 | 0.92 | +39.2% | ||||||
| Shares, m | 5 | 5 | 18 | 0 | 0 | 1 | 1 | 1 | 1 | 3 | 5 | (5.3%) | ||||||
| Valuation, × | ||||||||||||||||||
| Valuation, × | P/E | — | — | 0.00 | 0.00 | — | — | — | — | — | — | 0.00 | 0.0 | |||||
| P/S | — | — | 0.00 | 165.48 | — | — | — | — | — | — | 60.54 | 82.7 | ||||||
| P/B | — | — | 0.00 | 1.06 | — | — | — | — | — | — | 2.30 | 0.5 | ||||||
| EV/Sales | — | — | 0.00 | 139.74 | — | — | — | — | — | — | 18.50 | 69.9 | ||||||
| EV/FCF | — | — | 0.00 | (2.29) | — | — | — | — | — | — | (0.47) | (1.1) | ||||||
| Cash, $m | ||||||||||||||||||
| Cash, $m | Operating cash flow | 0 | 0 | (14) | (14) | (19) | (21) | (28) | (11) | (7) | (8) | (5) | +68.6% | |||||
| Capex | — | (8) | (3) | (1) | — | 0 | 0 | — | (1) | (3) | (3) | (10.6%) | ||||||
| Free cash flow | 0 | 0 | (17) | (14) | (19) | (21) | (29) | (11) | (8) | (11) | (9) | +74.7% | ||||||
| Balance, $m | ||||||||||||||||||
| Balance, $m | Working capital | 0 | 4 | 16 | 2 | 21 | 37 | 10 | 7 | 5 | 0 | 2 | n/m | |||||
| Net debt | 0 | (5) | (16) | (6) | (18) | (35) | (17) | (4) | (8) | (5) | (10) | +74.8% | ||||||
| Shareholders’ equity | 0 | 12 | 39 | 36 | 36 | 54 | 31 | 13 | 10 | 5 | 6 | +31.8% | ||||||
| Returns, % | ||||||||||||||||||
| Returns, % | ROA | (2.46) | (998.87) | (84.60) | (93.24) | (74.66) | (67.25) | (46.57) | (64.07) | (82.11) | (185.11) | (169.48) | (182.6) pt | |||||
| ROIC | 0.00 | 0.00 | (68.52) | (46.36) | (102.12) | (112.70) | (126.63) | (158.24) | (423.62) | (1,823.10) | 0.00 | (1,823.1) pt | ||||||
| ROE | (2.76) | (54.91) | (67.67) | (103.45) | (87.62) | (78.03) | (55.76) | (82.40) | (121.65) | (336.82) | (618.06) | (334.1) pt | ||||||
| People | ||||||||||||||||||
| People | Employees | — | — | 23 | 17 | 9 | 10 | 10 | 8 | 7 | 7 | — | (15.6%) | |||||
| Revenue/emp, $m | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | n/m | ||||||
Negative figures in brackets.
estimates
Fiscal years to Dec 2018 · latest quarter Sep 2019 · fundamentals updated 26 Oct 2026
Quantum Biopharma Ltd. vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| QNRX Quoin Pharmaceuticals, Ltd. Sponsored ADR | $18.5M | — (loss-making) | — | — | n/m | −510.28% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| ACTU Actuate Therapeutics, Inc. | $18.0M | — (loss-making) | — | — | n/m | −5.54% (below 0%: shrinking) | — | 0.00% | Compare |
| ESLA Estrella Immunopharma, Inc. | $17.8M | — (loss-making) | — | — | n/m | −329.19% (below 0%: shrinking) | — | 0.00% | Compare |
| KTTA Pasithea Therapeutics Corp. | $17.4M | — (loss-making) | — (loss-making) | +1,494.04% (above 0%: growing) | n/m | −21.68% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| CNTX Context Therapeutics Inc. | $17.3M | — (loss-making) | — | — | n/m | −20.61% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| QNTM Quantum Biopharma Ltd. | $17.1M | — (loss-making) | — (loss-making) | — | n/m | +5.88% (above 0%: growing) | 0.00% | 0.00% | |
| JSPR Jasper Therapeutics, Inc. | $15.6M | — (loss-making) | — | — | n/m | +55.74% (above 0%: growing) | 0.00% | 0.00% | Compare |
| NCEL NewcelX Ltd. | $15.6M | — (loss-making) | — | — | n/m | −87.71% (below 0%: shrinking) | 0.00% | — | Compare |
| ALLR Allarity Therapeutics, Inc. | $15.5M | — (loss-making) | — (loss-making) | — | n/m | +53.22% (above 0%: growing) | 100.00% | 0.00% | Compare |
| Median of peers | $17.3M | — | — | — | — | −21.14% | 0.00% | 0.00% |